卵巢转移瘤的研究进展  

作　　者：贺凤喜 张丽丽[1] 李爱华[1] 

机构地区：[1]聊城市人民医院,252000 [2]泰山医学院

出　　处：《妇产与遗传（电子版）》2017年第4期49-52,共4页Obstetrics-Gynecology and Genetics (Electronic Edition)

摘　　要：卵巢转移瘤占卵巢恶性肿瘤的10%~25%,大多数来源于乳腺癌、结肠癌、子宫内膜癌、胃癌和阑尾癌,容易误诊为原发性卵巢癌。免疫组织化学染色是主要鉴别诊断方法,基因表达谱分析是重要补充,卵巢转移瘤患者预后较差,肿瘤细胞减灭术对于部分患者有益。Secondary tumors of the ovary （ STOs） account for 10%~25% of all ovarian malignancies. The most common tumors that give rise to ovarian metastases include breast, colorectal, endometrial, stomach, and appendix cancer, and which are infrequently misdiagnosed as primary ovarian cancer. Immunohistochemistry plays an important role in distinguishing primary ovarian tumors from extra-ovarian metastases and, furthermore, gene expression profiling has been proven effective in determining the origin of cancer of unknown primary site. Patients with STOs have a generally poor prognosis, cytoreductive surgery may provide a survival benefit in select sub-groups of patients.

关 键 词：卵巢转移瘤 免疫组织化学 预后 肿瘤细胞减灭术 

分 类 号：R737.31[医药卫生—肿瘤]